Cite
HARVARD Citation
Autio, K. et al. (2023). First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer. 11 (3), p. . [Online].